19 February 2020

KWM advises on Sino Biopharmaceutical Limited’s €750 million convertible bonds

King & Wood Mallesons (KWM) advised Sino Biopharmaceutical Limited (Sino Biopharmaceutical, SEHK Stock Code: 1177) on its first-time issuance of €750 million zero coupon convertible bonds due 2025. Citigroup Global Markets Limited, The Hongkong and Shanghai Banking Corporation Limited, UBS AG Hong Kong Branch, J.P. Morgan Securities Plc and Goldman Sachs (Asia) L.L.C. were the joint global coordinators, joint bookrunners and joint lead managers of the transaction. The convertible bonds were listed on Hong Kong Stock Exchange. 

Sino Biopharmaceutical is a leading, innovative and research and development driven pharmaceutical conglomerate in the PRC. It was selected as a constituent stock of the Hang Seng Index in 2018 and a constituent stock of the Hang Seng China Enterprises Index in 2019.

KWM acted for Sino Biopharmaceutical in respect of Hong Kong, English and PRC laws. The team was led by Hong Kong partners Ng Ching-wo, Sheldon Tse, Richard Mazzochi and Shanghai partner Liu Dongya. The team was supported by counsel Ian Hardee and Sheryl Cheung, senior associate Eric Lo, and associates Stefy Tong, Christine Lau, Katherine Yang, Evangeline Chee and Wang Xiaowei.

*Any reference to “Hong Kong” or “Hong Kong SAR” shall be construed as a reference to “Hong Kong Special Administrative Region of the People’s Republic of China”.

Media contact

Share on LinkedIn Share on Facebook Share on Twitter
    You might also be interested in

    KWM has been recognised as the leading law firm in the Asia Pacific, ranking first in the 2020 Acritas Asia Pacific Brand Index.

    08 September 2020

    We have advised China Merchants Securities on its A+H shares rights issue.

    20 August 2020

    King & Wood Mallesons (KWM) continues to support long-term client China Molybdenum Co., Ltd on its global growth, as Australian and Hong Kong counsel on its US$550 million streaming transaction...

    22 July 2020

    We are pleased to have advised the sole sponsor and the underwriters on China New Energy Limited’s Hong Kong IPO.

    15 July 2020

    This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

    For more information on which cookies we use then please refer to our Cookie Policy.